DURECT Corporation

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

A cluster of recent breakthrough therapy designation awards in liver disease highlight advances in the field ahead of the US Food and Drug Administration’s difficult, and now delayed, decision on the

DURECT Corporation got disappointing Phase IIb data for its epigenetic modulator larsucosterol in alcohol-associated hepatitis (AH) on 7 November, but is hoping to convince both the US Food and Drug

Companies that are developing local anesthetic products intended to have a long-acting effect should collect trial data on “clinically meaningful outcomes,” such as reduction in hospitalization, even